PubMed
Kisspeptin signaling in reproductive biology
Pinilla L, Aguilar E, Dieguez C, et al. Physiol Rev. 2012
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 56% · Mixed 28% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 10–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 66% said they felt similar to their last entry, 36% more positive, and 16% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 284 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 60% · Mixed 26% · Unfavorable overall 14%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.1–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 107 repeat reporters
Published sources linked on the Kisspeptin and TB-500 wiki pages.
PubMed
Pinilla L, Aguilar E, Dieguez C, et al. Physiol Rev. 2012
PubMed
Skorupskaite K, George JT, Anderson RA. Fertil Steril. 2018
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Abreu AP, Kaiser UB. The lancet. Diabetes & endocrinology. 2016
PubMed
Hameed S, Jayasena CN, Dhillo WS. The Journal of endocrinology. 2011
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
PubMed
Smart N, Riley PR. Ann N Y Acad Sci. 2012
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012
PubMed
Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007
PubMed
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026
PubMed
Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026